Analysis of 4 studies [18, 20, 22, 24] with a total of 265 patients showed that the 5-year survival rate in DLBCL patients with DAPK methylation was not significantly different from those without methylation (RR = 0.90, 95% CI (0.62, 1.29), P = 0.557) (Fig 4A). This evidence concerns the gene DAPK1 and diffuse large B-cell lymphoma.